Document resource
MCBs are commercially available HPN preparation, licenced ‘standardised bags’ for use in both the adult and paediatric population. MCBs are used routinely in the adult population, but less commonly in paediatrics. The national framework for HPN commissioned by NHS England recommends that MCBs should be considered as a first line option in the paediatric population, unless otherwise clinically indicated. 1 Currently, no patients requiring HPN at our major centre are prescribed MCBs, largely due to insufficient micronutrient provision. Large patient numbers, along with increased pressure on the pharmacy compounding units,2 demonstrate the need for further consideration for the use of MCBs routinely in clinical practice, whilst ensuring that care can still be delivered safely and effectively.The aim of this national survey was to understand the current use of MCBs in the UK and identify common barriers for implementing their use. Data was collected on the current use of MCB at other paediatric HPN centres in the UK and determine their experience of this.An electronic survey was sent via email to dietitians working at all 21 paediatric HPN centres across the UK in January 2024. Answers were anonymised.15/21 centres responded (71% response rate), of which 13% are currently using MCBs. 47% reported they intended to move towards the routine use of MCBs in the future. Six patients from two centres in total are on MCBs. No child <10kg were prescribed an MCB. No centre reported changing to an MCB when approaching transition to adult services. 33% responded on whether micronutrients were added to MCBs prior to delivery, although only 13% were using MCBS so likely respondents were conflating answers with inpatient use of PN. 3/15 (20%) respondents reported micronutrients being added to MCBs prior to delivery to patients home whilst 2/15 (13%) reported enteral supplementation was provided.Whilst few centres are currently using MCBs in practice, a total of 60% report futures plans to implement these for paediatric HPN patients where clinically indicated. Children with a weight >10kg are likely to be favourable candidates. Also, careful consideration should be given to a plausible micronutrient plan. Industry needs to also play a role in providing MCBs which are more tailored to the paediatric population. This survey was limited in that respondents are likely to be conflating HPN with inpatient PN despite clear signposting on each question.The evidence for use of MCBs to reduce burden on aseptic units is growing. UK centres should play an active role in supporting patients transition to MCBs where appropriate.References Commissioning statement. Parenteral nutrition for the treatment of adults and children with Type 2 and Type 3 intestinal failure requiring home parenteral support [Internet]. Available from: https://www.england.nhs.uk/wp-content/uploads/2023/10/2267-hpn-commissioning-statement.pdfTransforming NHS Pharmacy Aseptic Services in England A national report for the Department of Health and Social Care by Lord Carter of Coles Contents [Internet]. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/931195/aseptic-pharmacy.pdf